Intelligence Report · ~12 min read

Merck Intelligence Report

Generated from 67 signals · 13 evidence sources

Type

Company Intelligence Report

Generated

Jun 20, 2026

Confidence

Moderate Confidence · 67%

Evidence

381 items

Sources

153

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Merck maintains an active intelligence profile across Oncology, Immune Checkpoint Inhibitor, Small Molecule, ALK Inhibitor, Non-Small Cell Lung Cancer. 67 signals are linked with 20 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 67% across 13 tracked sources. Highest-priority development: Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer. Portfolio development. Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer is an owned Merck portfolio development in Oncology · NSCLC.

Key Developments

Material intelligence events ranked by strategic relevance.

investigateJun 17, 2026
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV) · opportunity score 267
View detail
investigateJun 16, 2026
Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV · opportunity score 262
View detail
investigateJun 16, 2026
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC · opportunity score 262
View detail
investigateJun 17, 2026
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Oncology · Immune-Mobilizing T-cell Receptors · opportunity score 260
View detail
investigateJun 16, 2026
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Oncology · Prostate Cancer · opportunity score 260
View detail
investigateJun 16, 2026
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Oncology · ADC · opportunity score 260
View detail
investigateJun 16, 2026
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Oncology · Breast Cancer · opportunity score 260
View detail
investigateJun 16, 2026
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Oncology · Breast Cancer · opportunity score 260
View detail
investigateJun 11, 2026
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Oncology · Immunotherapy · opportunity score 260
View detail
investigateJun 17, 2026
FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment
Oncology · Bladder Cancer · opportunity score 257
View detail
investigateJun 16, 2026
FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns
Oncology · Breast Cancer · opportunity score 257
View detail
investigateJun 16, 2026
FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC
Oncology · KRAS G12C Inhibitor · opportunity score 257
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 17131 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 20 investigate-priority signals warrant near-term portfolio review. Competitiva linkage surfaces 7 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
Moderate Confidence · 68%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Moderate Confidence · 77%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
High Confidence · 95%
Potential competitive pressure
Source: Merck, Competitiva
View evidence
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
High Confidence · 95%
Potential competitive pressure
Source: Humanexa Signals, Competitiva
View evidence
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
Moderate Confidence · 82%
Potential competitive pressure
Source: Merck, Competitiva
View evidence
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Moderate Confidence · 73%
Potential competitive pressure
Source: Merck, Competitiva
View evidence
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Moderate Confidence · 73%
Potential competitive pressure
Source: Merck, Competitiva
View evidence
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Low Confidence · 0%
FDA approval
Source: Merck, ClinicalTrials.gov, Portfolio
View evidence
FDA Accepts Supplement Application for YERVOY (ipilimumab)
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, FDA, Portfolio
View evidence
RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
Low Confidence · 0%
FDA approval
Source: Merck, ClinicalTrials.gov, Portfolio
View evidence
OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer
Low Confidence · 0%
FDA approval
Source: Merck, Roche, Portfolio
View evidence
FDA Acceptance of NDA for Capivasertib by AstraZeneca
Low Confidence · 0%
FDA approval
Source: Merck, FDA, Portfolio
View evidence
Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026
Low Confidence · 0%
Phase III success
Source: Humanexa Signals, Lilly, Portfolio
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV)
Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Oncology · Immune-Mobilizing T-cell Receptors
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Oncology · NSCLC
NeoAdjuvant Therapy Trial for TNBC: Sacituzumab Govitecan + Pembrolizumab
Oncology · Triple-Negative Breast Cancer
CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial
Oncology · Melanoma
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Oncology · Prostate Cancer

Assets

ALECENSA
Portfolio asset

Executive Summary

Key Developments

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Strategic Implications

Supporting Evidence

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

FDA Accepts Supplement Application for YERVOY (ipilimumab)

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

FDA Acceptance of NDA for Capivasertib by AstraZeneca

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

Related Intelligence

Signals

Assets